

# Christine Lacabartz

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/921190/publications.pdf>

Version: 2024-02-01

22  
papers

767  
citations

840776

11  
h-index

752698

20  
g-index

25  
all docs

25  
docs citations

25  
times ranked

1377  
citing authors

#	ARTICLE	IF	CITATIONS
1	Preserved Central Memory and Activated Effector Memory CD4 <sup>+</sup> T-Cell Subsets in Human Immunodeficiency Virus Controllers: an ANRS EP36 Study. <i>Journal of Virology</i> , 2007, 81, 13904-13915.	3.4	164
2	Safety and immunogenicity of a two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Europe (EBOVAC2): a randomised, observer-blind, participant-blind, placebo-controlled, phase 2 trial. <i>Lancet Infectious Diseases</i> , The, 2021, 21, 493-506.	9.1	115
3	Prevention of Ebola virus disease through vaccination: where we are in 2018. <i>Lancet</i> , The, 2018, 392, 787-790.	13.7	103
4	Dendritic cell-based therapeutic vaccine elicits polyfunctional HIV-specific T <sub>H</sub> cell immunity associated with control of viral load. <i>European Journal of Immunology</i> , 2014, 44, 2802-2810.	2.9	102
5	Immune Alterations in a Patient with SARS-CoV-2-Related Acute Respiratory Distress Syndrome. <i>Journal of Clinical Immunology</i> , 2020, 40, 1082-1092.	3.8	48
6	Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in healthy and HIV-infected adults: A randomised, placebo-controlled Phase II clinical trial in Africa. <i>PLoS Medicine</i> , 2021, 18, e1003813.	8.4	34
7	Superiority in Rhesus Macaques of Targeting HIV-1 Env gp140 to CD40 versus LOX-1 in Combination with Replication-Competent NYVAC-KC for Induction of Env-Specific Antibody and T Cell Responses. <i>Journal of Virology</i> , 2017, 91, .	3.4	29
8	Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in children and adolescents in Africa: A randomised, placebo-controlled, multicentre Phase II clinical trial. <i>PLoS Medicine</i> , 2022, 19, e1003865.	8.4	27
9	Anti-HIV potency of T-cell responses elicited by dendritic cell therapeutic vaccination. <i>PLoS Pathogens</i> , 2019, 15, e1008011.	4.7	25
10	Targeting SARS-CoV-2 receptor-binding domain to cells expressing CD40 improves protection to infection in convalescent macaques. <i>Nature Communications</i> , 2021, 12, 5215.	12.8	22
11	Cytokine and gene transcription profiles of immune responses elicited by HIV lipopeptide vaccine in HIV-negative volunteers. <i>Aids</i> , 2013, 27, 1421-1431.	2.2	16
12	Durable natural killer cell responses after heterologous two-dose Ebola vaccination. <i>Npj Vaccines</i> , 2021, 6, 19.	6.0	12
13	HIV-1 T cell epitopes targeted to Rhesus macaque CD40 and DCIR: A comparative study of prototype dendritic cell targeting therapeutic vaccine candidates. <i>PLoS ONE</i> , 2018, 13, e0207794.	2.5	11
14	Optimal priming of poxvirus vector (NYVAC)-based HIV vaccine regimens for T cell responses requires three DNA injections. Results of the randomized multicentre EV03/ANRS VAC20 Phase I/II Trial. <i>PLoS Pathogens</i> , 2020, 16, e1008522.	4.7	11
15	Optimization and evaluation of Luminex performance with supernatants of antigen-stimulated peripheral blood mononuclear cells. <i>BMC Immunology</i> , 2016, 17, 44.	2.2	10
16	Design, immunogenicity, and efficacy of a pan-sarbecovirus dendritic-cell targeting vaccine. <i>EBioMedicine</i> , 2022, 80, 104062.	6.1	10
17	T Cell Immunogenicity, Gene Expression Profile, and Safety of Four Heterologous Prime-Boost Combinations of HIV Vaccine Candidates in Healthy Volunteers: Results of the Randomized Multi-Arm Phase I/II ANRS VRI01 Trial. <i>Journal of Immunology</i> , 2022, 208, 2663-2674.	0.8	8
18	Targeting human langerin promotes HIV-1 specific humoral immune responses. <i>PLoS Pathogens</i> , 2021, 17, e1009749.	4.7	7

#	ARTICLE	IF	CITATIONS
19	Modelling the response to vaccine in non-human primates to define SARS-CoV-2 mechanistic correlates of protection. <i>ELife</i> , 0, 11, .	6.0	7
20	Serum suppression of tumorigenicity 2 level is an independent predictor of all-cause mortality in HIV-infected patients. <i>Aids</i> , 2017, 31, 2355-2365.	2.2	4
21	Profound Defect of Amphiregulin Secretion by Regulatory T Cells in the Gut of HIV-Treated Patients. <i>Journal of Immunology</i> , 2022, 208, 2300-2308.	0.8	1
22	NK Cell Subset Redistribution and Antibody Dependent Activation after Ebola Vaccination in Africans. <i>Vaccines</i> , 2022, 10, 884.	4.4	1